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Incidence and outcome of acute renal failure complicating au- AL amyloidosis is a systemic disease in which clonal
tologous stem cell transplantation for AL amyloidosis. plasma cells produce monoclonal light chains that de-
Background. High-dose intravenous melphalan and autolo- posit in tissues as amyloid fibrils. The amyloid depositiongous peripheral blood stem cell transplantation (HDM/SCT)
results in progressive dysfunction of involved organs. Theis an effective treatment for AL amyloidosis but is associated
response to standard treatment consisting of repeatedwith significant toxicity, including the development of acute
renal failure (ARF). The incidence and outcome of ARF as a cycles of orally administered melphalan and prednisone
complication of such treatment is not known. is unsatisfactory with rare eradication of the plasma cell
Methods. All AL amyloidosis patients treated with HDM/ dyscrasia and a median survival of only 16 to 18 monthsSCT at a single institution between July 1, 1994 and May 31,
[1, 2]. Myeloablative chemotherapy consisting of high-2000 were included in the analysis unless they were dialysis-
dose intravenous melphalan followed by autologous pe-dependent prior to treatment. Baseline data were collected
prospectively. Treatment-related data were obtained from a ripheral blood stem cell transplantation (HDM/SCT) is
prospectively maintained database and medical record review. emerging as a more effective treatment for AL amyloi-
ARF was defined as either a 1 mg/dL increase in serum
dosis. At our institution, this treatment has yielded hema-creatinine or a doubling of serum creatinine to 1.5 mg/dL
tologic complete response rates of 40% to 50%, a medianfor at least 2 days. Recovery of renal function was defined as
a return of serum creatinine to less than or within 0.5 mg/dL survival of longer than 4 years, and reductions in amy-
of the pretreatment value or the ability to discontinue dialysis loid-related organ dysfunction in a substantial propor-
initiated as a result of ARF. tion of patients [3–6]. Among patients with renal involve-
Results. ARF occurred in 37 of 173 patients (21%). Initiation
ment, achievement of a hematologic complete responseof dialysis was required in nine patients (5%). Forty-six percent
was associated with a 50% reduction in proteinuriaof patients with ARF, including four of nine who required
dialysis, had recovery of renal function. Baseline clinical vari- and stable creatinine clearance in 71% of patients [6].
ables that were independent predictors of transplant-associated The toxicities of IVM/SCT are significant and due, in
ARF included creatinine clearance, proteinuria, and cardiac part, to the organ dysfunction present in AL amyloidosisamyloidosis. Treatment-related variables associated with ARF
patients. This organ dysfunction distinguishes AL amy-included melphalan dose and bacteremia. ARF was associated
loidosis from most diseases for which autologous stemwith reduced survival at 90 days but did not have an impact
on overall survival at a median follow-up of 2.9 years. cell transplantation is performed. Renal insufficiency, he-
Conclusion. ARF is a frequent but often reversible compli- patic dysfunction, and cardiac disease are usually exclu-
cation of HDM/SCT for AL amyloidosis. Specific clinical and sion criteria for chemotherapy protocols that requiretreatment-related factors are associated with the development
hematopoietic stem cell support but are present aloneof this complication.
or in combination in the majority of patients with AL
amyloidosis. Bleeding tendencies, peripheral edema due
to nephrotic syndrome, and orthostatic hypotension are
additional features of AL amyloidosis typically not pres-
ent in patients undergoing aggressive chemotherapy regi-
mens for malignancies. Not surprisingly, peritransplantKey words: AL amyloidosis, acute renal failure, autologous stem cell
transplantation, chemotherapy, melphalan. mortality rates are highest among AL amyloidosis pa-
tients with cardiac involvement [3] (Skinner et al, unpub-Received for publicationAugust 21, 2002
lished data).and in revised form October 23, 2002, and November 23, 2002
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of 65 AL amyloidosis patients with underlying renal Treatment
involvement [6]. The purpose of the present study was Peripheral blood stem cells were mobilized using gran-
to determine the incidence of ARF among all AL amyloi- ulocyte-colony stimulating factor (G-CSF) (Filgrastim;
dosis patients undergoing this treatment at our institu- Amgen, Thousand Oaks, CA, USA), 10 to 16 g/kg as
tion and to identify the etiologies and risk factors for the sole mobilizing agent or in combination with granu-
this treatment complication. locyte macroghage-colony stimulating factor (GM-CSF)
(Sargamostim, Immunex, Seattle, WA, USA), 250 g/m2
as previously described [3, 4]. Melphalan was adminis-METHODS
tered intravenously in divided doses on 2 consecutive
Patients days. Melphalan dose (100, 140, or 200 mg/m2) was deter-
Patients with AL amyloidosis treated with HDM/SCT mined by protocol, dependent on age, cardiac status, and
during the period from July 1994 through May 2000 performance status. Stem cells were infused 24 to 72
were included in the analysis unless they were dialysis- hours after melphalan administration with administra-
dependent prior to treatment. The diagnosis of AL amy- tion of daily G-CSF (5 mg/kg) and epoietin (50 U/kg)
loidosis required demonstration of tissue amyloid depos- three times a week to promote hematologic recovery.
its by Congo red staining and the presence of a plasma Prophylactic antibiotics consisting of oral levofloxacin
cell dyscrasia by the finding of a monoclonal immuno- and acyclovir were used in all patients. Treatment was
globulin protein by serum or urine immunofixation elec- performed in the outpatient setting with hospitalization
trophoresis, and/or evidence of clonal plasmacytosis by only if needed for treatment- or disease-related compli-
bone marrow biopsy. Patients were treated under a series cations.
of protocols approved by the Institutional Review Board
Outcome measuresof Boston University Medical Center. Eligibility criteria
for treatment included age18 years, left ventricular ejec- ARF was defined as either an increase in the baseline
tion fraction 40%, supine blood pressure 90 mm Hg, serum creatinine of1 mg/dL or a doubling of the base-
room air oxygen saturation95%, and performance sta- line serum creatinine to at least 1.5 mg/dL. The elevation
tus 3 according to the Southwest Oncology Group in creatinine had to be sustained for at least 2 days during
(SWOG) [7], unless the functional limitation was caused the period between the initial dose of G-CSF for stem
by peripheral neuropathy. For most of the protocols cell mobilization and 30 days following stem cell infusion.
there was no limitation by age or renal function. The date of stem cell infusion is referred to as day 0.
Recovery of renal function was defined as a reduction
Data collection in serum creatinine to less than or within 0.5 mg/dL of
Baseline clinical and laboratory data were collected the baseline value, or discontinuation of dialysis that had
prospectively. Creatinine clearance was determined from been initiated because of transplant-associated ARF.
24-hour urine collections. Amyloid organ involvement Recovery of renal function was ascertained from labora-
was determined at the time of initial evaluation by a multi- tory studies performed when patients returned for evalu-
disciplinary team that included subspecialists in rheuma- ation 3 months after day 0. If a 3-month evaluation did
tology, nephrology, hematology/oncology, cardiology, not take place the last available creatinine value prior
pulmonary, and neurology according to previously de- to 3 months following day 0 was used for assessment of
scribed criteria [3]. Renal involvement was defined by ARF recovery.
urinary protein excretion 500 mg/24 hours or elevated
Etiology of ARFserum creatinine concentration in the absence of other
renal disease. Cardiac involvement was defined by septal Detailed medical record review was performed for all
or posterior wall thickening 12 mm by echocardiogra- patients who developed ARF in order to identify etio-
phy in the absence of a history of hypertension or under- logic factors. The following data or events were recorded:
lying cardiac disease, or by amyloid-related congestive administration of nephrotoxic medications or medica-
heart failure or arrythmia. Treatment-related data were tions that alter intrarenal hemodynamics (intravenous
obtained from a prospectively maintained database of contrast, intravenous acyclovir, aminoglycosides, angio-
the Stem Cell Transplantation Program and by medical tensin-converting enzyme inhibitors, angiotensin recep-
record review. Data abstraction from medical records tor antagonists), peak white blood cell count following
was performed by a single individual. Ten percent of growth factor administration for stem cell mobilization,
the records were randomly selected and reviewed by a date of white blood cell nadir, serum phosphate, calcium,
second member of the study team. The study was ap- and uric acid concentrations at white blood cell nadir,
proved by the Institutional Review Board of Boston bacteremia, other infections, gastrointestinal bleeding,
hemodynamic compromise, congestive heart failure, uri-University Medical Center.
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Table 1. Timing of acute renal failure (ARF) with respect to
treatment phases
High-dose chemotherapy treatment phase ARF cases, N (%)
Stem cell mobilization with growth factora 5 (13)
Melphalan administration/stem cell infusiona 21 (57)
After neutrophil engraftment 11 (30)
a Refers to the time period during or after the depicted treatment phase and
before the subsequent treatment phase
Table 2. Clinically apparent causes of acute renal failure (ARF)
among the 37 patients
Fig. 1. Serum creatinine values for the 37 patients with transplant-
associated acute renal failure. The follow-up value is the creatinine Cause or contributor Numbera
obtained at the evaluation 3 months following day 0. If a 3-month
Bacteremiab 11evaluation did not occur, the follow-up creatinine value is the last
Medicationsc 15available creatinine measurement prior to 3 months.
Hemodynamic compromised 25
White blood cell lysise 5
Acute tubular necrosis evident by urine sediment 13
Unknown 8
nalysis results, and the impression of consulting nephrol- a Total number is greater than 34 because multiple contributors to ARF were
present in some patientsogists. White blood cell lysis was considered to be the
b Organisms included Staphylococcus epidermidis, Streptococcus sanguis, Kleb-cause or a contributor to ARF if the white blood cell siella pneumoniae, Enterococcus faecalis, and a Bacillus species
c Medications included gentamicin, acyclovir (intravenously administered), ra-nadir occurred within 4 days prior to the ARF-defining
diographic contrast, or angiotensin-converting enzyme (ACE) inhibitorscreatinine elevation and was accompanied by hyperphos- d Causes of hemodynamic compromise included vomiting, diarrhea, autonomic
nervous system dysfunction, congestive heart failure, or gastrointestinal bleedingphatemia (phosphate 7.0 mg/dL), hypocalcemia (cal-
e See Methods section for definitioncium8.0 mg/dL after correction for serum albumin con-
centration), and hyperuricemia (uric acid 7.0 mg/dL).
Statistical analysis ery of renal function occurred in 17 of the 37 ARF pa-
tients (46%). Nine patients (5% of entire cohort, 24%Baseline characteristics were compared using the chi-
of ARF patients) required initiation of dialysis as a resultsquare test for categoric variables, and two sample t tests
of transplant-associated ARF. The dialysis modalitiesfor continuous variables. Univariate analysis was per-
used were intermittent hemodialysis (three to five timesformed with baseline characteristics as independent vari-
per week) for five patients, continuous hemodiafiltrationables and ARF as the dependent variable. Multivariable
for three patients, and peritoneal dialysis for one patient.models were developed using those independent vari-
Discontinuation of dialysis was possible in four of theseables found by univariate analysis to have an association
patients and occurred at 2, 7, 8, and 25 weeks followingat a significance level of 0.2. Survival curves were gen-
day 0.erated using Kaplan-Meier techniques and compared
The clinically apparent causes of ARF are shown inwith the log-rank test. Analyses used a two-tailed signifi-
Table 2. In most patients multiple factors were thought to
cance value of 0.05 unless otherwise indicated and were contribute to the development of renal failure. Urinary
performed using NCSS statistical software (NCSS 2001, sediment findings suggestive of acute tubular necrosis
Kaysville UT, USA). (i.e., granular casts and renal tubular epithelial cells)
were present in 13 (35%) of the 37 patients. A white
blood cell lysis syndrome resulting from melphalan ad-RESULTS
ministration in the setting of marked growth factor–Incidence, outcome, and etiology of ARF
induced leukocytosis was thought to cause or contribute
A total of 173 nondialysis-dependent patients under- to ARF in five patients (14%).
went HDM/SCT during the study period. ARF occurred The medical records of 10% of the ARF patients were
in 37 (21%) of these patients. Baseline, peak, and follow- selected at random and reviewed by a second member
up creatinine values for the individual patients with ARF of the study team who had no knowledge of the data
are depicted in Figure 1. The median time to ARF from interpretation by the primary data abstractor. In each
day 0 was 7 days (range, –24 to 27 days) and the median case, identical assessments of onset, duration, outcome,
time from day 0 to peak creatinine was 11 days (range, and etiology of ARF were made by the two individuals.
–10 to 29 days). As shown in Table 1, most cases of ARF
Risk factors for ARFoccurred during or after the melphalan administration
and stem cell infusion phase of treatment, although sev- Baseline characteristics of the AL amyloidosis patients
treated with HDM/SCT are shown in Table 3. Eighty-eral cases occurred during stem cell mobilization. Recov-
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Table 3. Baseline and treatment characteristics of patients treated with high-dose melphalan and stem cell transplantation (HDM/SCT)a
All patients No acute renal Acute renal
(N  173) failure (N  136) failure (N  37) P valueb
Age years 5710 5710 559 0.30
Male % 58 62 43 0.04
Proteinuria g/24 hours 4.4 (0.06–27) 3.0 (0.06–22) 6.0 (0.1–27) 0.004
Serum creatinine mg/dL 1.1 (0.4–8.5) 1.0 (0.4–8.5) 1.5 (0.5–3.6) 0.001
Creatinine clearance mL/minc 73 (8–222) 78 (8–222) 47 (18–132) 0.001
Systolic blood pressure mm Hg 12125 12025 12622 0.21
Diastolic blood pressure mm Hg 7513 7413 7711 0.26
Light chain isotype: lambda/kappa % 82/18 82/18 84/16 0.76
Renal involvement % 82 77 100 0.002
Cardiac involvement % 47 43 62 0.04
Orthostatic hypotension % 16 13 27 0.04
Involved organ systems number 3 (1–7) 3 (1–7) 4 (2–7) 0.01
Melphalan dose mg/m2 200 (100–200) 200 (100–200)d 200 (100–200)d 0.04
Stem cell volume number of bags 6 (1–23) 6 (1–23) 6 (1–20) 0.29
aValues are expressed as mean standard deviation for normally distributed variables, median with range for nonnormally distributed variables, and percentage
where indicated
bFor comparisons between patients with acute renal failure and without acute renal failure
cCalculated from 24-hour urinary creatinine excretion
dThe melphalan dose is lower in the “No Acute Renal Failure” group than the “Acute Renal Failure” group
Table 4. Predictors of acute renal failure (ARF)
Univariate Multivariate model: Multivariate model: baseline and
analysis, odds ratio baseline variables,a treatment variables,a odds ratio
Parameter (95% CI) odds ratio (95% CI) (95% CI)
Age (per 10 years) 0.82 (0.57–1.19) 0.77 (0.48–1.24) 1.00 (0.58–1.78)
Female 2.12 (1.02–4.43)b 1.77 (0.74–4.26) 1.91 (0.75–4.90)
Proteinuria (per 1 g/24 hours) 1.11 (1.04–1.18)b 1.10 (1.02–1.18)b 1.08 (0.99–1.17)
Creatinine clearance (per 10 mL/min) 0.75 (0.65–0.86)b 0.75 (0.64–0.88)b 0.74 (0.62–0.88)b
Cardiac involvement 2.21 (1.05–4.66)b 2.40 (1.01–5.82)b 3.18 (1.21–8.34)b
Orthostatic hypotension 2.43 (1.01–5.85)b 2.49 (0.88–6.99) 1.98 (0.67–5.89)
Melphalan dose (200 vs. 100 to 140 mg/m2) 2.26 (1.02–5.04)b 3.34 (1.06–10.56)b
Bacteremia 6.6 (2.82–15.59)b 4.19 (1.43–12.27)b
Systolic blood pressure (per 10 mm Hg) 1.01 (0.99–1.03)
Diastolic blood pressure (per 10 mm Hg) 1.02 (0.99–1.05)
Stem cell volume (per five bags) 0.78 (0.50–1.22)
Number of involved organ systems (per one system) 1.30 (1.04–1.65)b
aVariables with a significance level of 0.2 in univariate analysis were included in the multivariate models with the exception of number of involved organ systems,
which was not included in multivariate models because of colinearity with cardiac involvement
bP  0.05
two percent of patients had baseline renal involvement male gender, higher urinary protein excretion, lower cre-
and the majority of patients had amyloid involvement of atinine clearance, presence of cardiac involvement, or-
more than two organ systems. Comparisons of baseline thostatic hypotension, higher number of involved organ
characteristics between patients who developed ARF systems, higher melphalan dose, and the development of
and those who did not revealed several differences. A bacteremia during the peritransplant period were each as-
greater proportion of patients with ARF were female and sociated with the development of ARF by univariate analy-
had cardiac involvement, renal involvement, and ortho- sis. Two multivariate models were created. The first model
static hypotension. In addition, the ARF patients had (Model 1) included only baseline clinical variables. The
greater urinary protein excretion, lower creatinine clear- second model (Model 2) included baseline clinical vari-
ance, and a greater number of organ systems involved at
ables and treatment-related variables. In Model 1, higherbaseline than the non-ARF patients. Four of the 37 pa-
urinary protein excretion, lower creatinine clearance,tients (11%) with ARF had baseline creatinine clearance
and presence of cardiac involvement were each indepen-95 mL/min. Among the ARF patients, there was no
dent predictors of ARF. In Model 2, melphalan dosedifference in baseline creatinine clearance between those
and development of bacteremia during the peritrans-who required dialysis and those who did not (mean 
plant period were additional independent predictors ofSD, 54  20 mL/min vs. 54  29 mL/min; P  0.98).
ARF, and the association between proteinuria and ARFResults of logistic regression analysis performed to
identify risk factors for ARF are shown in Table 4. Fe- was no longer statistically significant. Although number
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autologous peripheral blood stem cell transplantation
for Hodgkin’s disease, non-Hodgkin’s lymphoma, or
multiple myeloma, ARF developed in 15% [11]. The
lower incidence of ARF in the latter two series is likely
due to (1) the use of autologous rather than allogeneic
hematopoietic cells, which eliminates the possibility of
graft versus host disease and the need for nephrotoxic
immunosuppressive medications, and (2) the use of pe-
ripheral blood rather than bone marrow stem cells, which
reduces the duration of cytopenia and thus the incidence
of sepsis and/or need for nephrotoxic antimicrobial agents.
We found that 21% of AL amyloidosis patients treated
with HDM/SCT developed ARF between the time of
initiation of growth factor administration for stem cell
mobilization and 30 days following stem cell infusion.
Initiation of dialysis was required in approximately one
fourth of those with ARF. In nearly half of the patientsFig. 2. Survival from day 0 for patients with acute renal failure (ARF)
versus patients without ARF. P  0.43 by log-rank test. with ARF, recovery of renal function was evident within
3 months of its onset, and among those requiring renal
replacement therapy discontinuation of dialysis occurred
in 44%. Although the development of ARF was not asso-
of organ systems involved at baseline was a predictor of
ciated with reduced overall survival, it was associated
ARF in univariate analysis, this variable was not included
with an increase in mortality at 90 days posttransplant.
in the final multivariable models because of colinearity
The identifiable etiologies of ARF in our cohort in-with cardiac involvement, a stronger predictor of ARF.
cluded hemodynamic stress, bacteremia, nephrotoxic
medications, allergic interstitial nephritis, and whitePatient survival
blood cell lysis. In many cases, several contributors wereThe relationship between transplant-associated ARF
identified and in 22% a cause of ARF was not evident.and survival is depicted in Figure 2. At a median follow-
Using predefined criteria, we attributed ARF to a whiteup of 2.9 years, survival was similar in the ARF and non-
blood cell lysis syndrome in five patients. We speculateARF groups (P  0.43); however, at 90 days after stem
that the rapid lysis of growth factor–induced white bloodcell transplant, survival was better among patients with-
cells that occurs following melphalan administration canout transplant-associated ARF (P  0.004). Of the nine
cause ARF in a manner similar to that of the tumor lysispatients who required initiation of dialysis as a result of
syndrome. Such a white blood cell lysis syndrome has nottransplant-associated ARF, five are alive at last follow-
been previously described in the stem cell transplantationup and two remain on chronic dialysis.
literature, perhaps because patients undergoing stem cell
transplantation for other diseases are less likely to de-
DISCUSSION velop ARF following chemotherapy-induced white blood
cell lysis than are AL amyloidosis patients who typicallyARF is a well-established complication of myeloabla-
have significant underlying organ dysfunction.tive chemotherapy regimens. In a retrospective series of
AL amyloidosis differs from most diseases treated272 patients treated with allogeneic bone marrow trans-
with dose-intensive chemotherapy regimens in that sin-plantation for leukemia or lymphoma, a doubling of the
gle or multiorgan dysfunction is present in virtually allserum creatinine occurred in 53% [8]. Many of the ARF
patients at the time of treatment. Particularly relevantpatients in that series received amphotericin B for pre-
to the development of ARF are several disease featuressumed or documented fungal infections and many had
such as heart failure, autonomic dysfunction, and thirdsepsis. A doubling of the serum creatinine occurred in
spacing of intravascular fluid, all of which are hemody-69% of 88 patients who received allogeneic hematopoi-
namic stresses that can either cause acute reductions inetic stem cell transplantation, and, in a substantial pro-
glomerular filtration rate (GFR) or increase susceptibil-portion of the surviving patients, the creatinine remained
ity to renal injury. Indeed, the presence of underlyingelevated at evaluation 6 months later [9]. The incidence
renal impairment and cardiac disease were each indepen-of ARF in a series of 232 patients with metastatic breast
dent risk factors for the development of ARF. Bacter-cancer treated with autologous transplantation using ei-
emia, a potential complication of all marrow-suppressivether peripheral blood (85%) or bone marrow (15%) stem
cells was 21% [10]. In a series of 53 patients treated with regimens, was one of the strongest risk factors for ARF
Fadia et al: ARF during stem cell transplantation for AL amyloidosis 1873
in our multivariate model that included treatment-associ- and may affect modifications in the treatment protocol,
such as melphalan dose reduction for those patients atated, as well as baseline, variables.
Several components of the HDM/SCT treatment regi- highest risk. Our findings may also have implications for
the use of high-dose chemotherapy regimens for othermen have the potential to cause ARF. The high doses of
G-CSF required for stem cell mobilization and marrow diseases such as systemic lupus erythematosis or systemic
sclerosis in which organ dysfunction will generally berecovery produce a capillary leak syndrome with third
spacing of intravascular fluid that can be particularly present at the time of dose-intensive chemotherapy.
marked in nephrotic patients or those with hypoalbumi-
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